Journal of Neuro-Oncology

, Volume 141, Issue 1, pp 121–129 | Cite as

Tubular brain tumor biopsy improves diagnostic yield for subcortical lesions

  • Evan D. Bander
  • Samuel H. Jones
  • David Pisapia
  • Rajiv Magge
  • Howard Fine
  • Theodore H. Schwartz
  • Rohan RamakrishnaEmail author
Clinical Study



Molecular data has become an essential part of the updated World Health Organization (WHO) grading of central nervous system tumors. However, stereotactic needle biopsies provide only small volume specimens and limit the extent of histologic and molecular testing that can be performed. We assessed the use of a tubular retractor-based minimally invasive biopsy technique to provide improved tissue yield and diagnostic data compared to needle biopsy.


Eighteen patients underwent an open transtubular biopsy compared to 146 stereotactic biopsies during the years of 2010–2018.


Tubular biopsies resulted in a higher volume of tissue provided to the pathologist than needle biopsies (1.26 cm3 vs. 0.3 cm3; p < 0.0001). There was a higher rate of non-diagnostic sample with stereotactic compared to transtubular biopsy (13% vs. 0%; p = 0.13). Six patients who underwent stereotactic biopsy required reoperation for diagnosis, while no transtubular biopsy patient required reoperation in order to obtain a diagnostic specimen. Postoperative hematoma was the most common post-operative complication in both groups.


Stereotactic transtubular biopsies are a viable alternative to stereotactic needle biopsies with excellent rates of diagnostic success and acceptable morbidity relative to the needle biopsy technique. As molecular data begins to increasingly drive treatment decisions, additional biopsy techniques that afford large tissue volumes may be necessary to adapt to the new needs of pathologists and treating oncologists.


Stereotactic Tubular Biopsy Neurosurgery Complication Hemorrhage 



The authors would like to acknowledge Debra D’Angelo for her contributions to the statistical analyses performed in this research.

Supplementary material

Supplementary material video (MP4 19628 KB)


  1. 1.
    Rahman M, Murad GJA, Mocco J (2009) Early history of the stereotactic apparatus in neurosurgery. Neurosurg Focus 27:E12. CrossRefGoogle Scholar
  2. 2.
    Krieger MD, Chandrasoma PT, Zee C-S, Apuzzo MLJ (1998) Role of stereotactic biopsy in the diagnosis and management of brain tumors. Semin Surg Oncol 14:13–25.;2-5 CrossRefGoogle Scholar
  3. 3.
    Kickingereder P, Willeit P, Simon T, Ruge MI (2013) Diagnostic value and safety of stereotactic biopsy for brainstem tumors: a systematic review and meta-analysis of 1480 cases. Neurosurgery 72:873–881. (discussion 882; quiz 882)CrossRefGoogle Scholar
  4. 4.
    Reithmeier T, Lopez WO, Doostkam S et al (2013) Intraindividual comparison of histopathological diagnosis obtained by stereotactic serial biopsy to open surgical resection specimen in patients with intracranial tumours. Clin Neurol Neurosurg 115:1955–1960. CrossRefGoogle Scholar
  5. 5.
    Lu Y, Yeung C, Radmanesh A et al (2015) Comparative effectiveness of frame-based, frameless, and intraoperative magnetic resonance imaging-guided brain biopsy techniques. World Neurosurg 83:261–268. CrossRefGoogle Scholar
  6. 6.
    Hall WA (1998) The safety and efficacy of stereotactic biopsy for intracranial lesions. Cancer 82:1749–1755.;2-2 CrossRefGoogle Scholar
  7. 7.
    Dammers R, Haitsma IK, Schouten JW et al (2008) Safety and efficacy of frameless and frame-based intracranial biopsy techniques. Acta Neurochir (Wien) 150:23–29. CrossRefGoogle Scholar
  8. 8.
    Khatab S, Spliet W, Woerdeman PA (2014) Frameless image-guided stereotactic brain biopsies: emphasis on diagnostic yield. Acta Neurochir (Wien) 156:1441–1450. CrossRefGoogle Scholar
  9. 9.
    Castle M, Nájera E, Samprón N et al (2014) Frameless stereotactic biopsy: diagnostic yield and complications. Neurocirugia (Asturias) 25:56–61. CrossRefGoogle Scholar
  10. 10.
    Muragaki Y, Chernov M, Maruyama T et al (2008) Low-grade glioma on stereotactic biopsy: how often is the diagnosis accurate? Minim Invasive Neurosurg MIN 51:275–279. CrossRefGoogle Scholar
  11. 11.
    Slowiński J, Harabin-Slowińska M, Mrówka R (1999) Smear technique in the intra-operative brain tumor diagnosis: its advantages and limitations. Neurol Res 21:121–124CrossRefGoogle Scholar
  12. 12.
    Herrera SR, Shin JH, Chan M et al (2010) Use of transparent plastic tubular retractor in surgery for deep brain lesions: a case series. Surg Technol Int 19:47–50Google Scholar
  13. 13.
    Recinos PF, Raza SM, Jallo GI, Recinos VR (2011) Use of a minimally invasive tubular retraction system for deep-seated tumors in pediatric patients. J Neurosurg Pediatr 7:516–521. CrossRefGoogle Scholar
  14. 14.
    Jo K-W, Shin HJ, Nam D-H et al (2011) Efficacy of endoport-guided endoscopic resection for deep-seated brain lesions. Neurosurg Rev 34:457–463. CrossRefGoogle Scholar
  15. 15.
    Ichinose T, Goto T, Morisako H et al (2010) Microroll retractor for surgical resection of brainstem cavernomas. World Neurosurg 73:520–522. CrossRefGoogle Scholar
  16. 16.
    Ratre S, Yadav YR, Parihar VS, Kher Y (2016) Microendoscopic removal of deep-seated brain tumors using tubular retraction system. J Neurol Surg A 77:312–320. CrossRefGoogle Scholar
  17. 17.
    Jo K-I, Chung SB, Jo K-W et al (2011) Microsurgical resection of deep-seated lesions using transparent tubular retractor: pediatric case series. Childs Nerv Syst 27:1989–1994. CrossRefGoogle Scholar
  18. 18.
    Kreth FW, Muacevic A, Medele R et al (2001) The risk of haemorrhage after image guided stereotactic biopsy of intra-axial brain tumours–a prospective study. Acta Neurochir (Wien) 143:539–545 (discussion 545–546)CrossRefGoogle Scholar
  19. 19.
    Akai T, Shiraga S, Sasagawa Y et al (2008) Intra-parenchymal tumor biopsy using neuroendoscopy with navigation. Minim Invasive Neurosurg MIN 51:83–86. CrossRefGoogle Scholar
  20. 20.
    Almenawer SA, Crevier L, Murty N et al (2013) Minimal access to deep intracranial lesions using a serial dilatation technique: case-series and review of brain tubular retractor systems. Neurosurg Rev 36:321–330. CrossRefGoogle Scholar
  21. 21.
    Fahim DK, Relyea K, Nayar VV et al (2009) Transtubular microendoscopic approach for resection of a choroidal arteriovenous malformation. J Neurosurg Pediatr 3:101–104. CrossRefGoogle Scholar
  22. 22.
    Greenfield JP, Cobb WS, Tsouris AJ, Schwartz TH (2008) Stereotactic minimally invasive tubular retractor system for deep brain lesions. Neurosurgery 63:334–339. (discussion 339–340)CrossRefGoogle Scholar
  23. 23.
    Jho H-D, Alfieri A (2002) Endoscopic removal of third ventricular tumors: a technical note. Minim Invasive Neurosurg MIN 45:114–119. CrossRefGoogle Scholar
  24. 24.
    Kassam AB, Engh JA, Mintz AH, Prevedello DM (2009) Completely endoscopic resection of intraparenchymal brain tumors. J Neurosurg 110:116–123. CrossRefGoogle Scholar
  25. 25.
    Kelly PJ (1989) Future perspectives in stereotactic neurosurgery: stereotactic microsurgical removal of deep brain tumors. J Neurosurg Sci 33:149–154Google Scholar
  26. 26.
    Kelly PJ, Goerss SJ, Kall BA (1988) The stereotaxic retractor in computer-assisted stereotaxic microsurgery. Technical note. J Neurosurg 69:301–306. CrossRefGoogle Scholar
  27. 27.
    Moshel YA, Link MJ, Kelly PJ (2007) Stereotactic volumetric resection of thalamic pilocytic astrocytomas. Neurosurgery 61:66–75. (discussion 75)CrossRefGoogle Scholar
  28. 28.
    Nishihara T, Nagata K, Tanaka S et al (2005) Newly developed endoscopic instruments for the removal of intracerebral hematoma. Neurocrit Care 2:67–74. CrossRefGoogle Scholar
  29. 29.
    Otsuki T, Jokura H, Yoshimoto T (1990) Stereotactic guiding tube for open-system endoscopy: a new approach for the stereotactic endoscopic resection of intra-axial brain tumors. Neurosurgery 27:326–330CrossRefGoogle Scholar
  30. 30.
    Patil A-A (1987) Stereotactic excision of deep brain lesions using probe guided brain retractor. Acta Neurochir (Wien) 87:150–152. CrossRefGoogle Scholar
  31. 31.
    Raza SM, Recinos PF, Avendano J et al (2011) Minimally invasive trans-portal resection of deep intracranial lesions. Minim Invasive Neurosurg MIN 54:5–11. CrossRefGoogle Scholar
  32. 32.
    Ross DA (1993) A simple stereotactic retractor for use with the Leksell stereotactic system. Neurosurgery 32:475–476 (discussion 476)CrossRefGoogle Scholar
  33. 33.
    Constantini S, Mohanty A, Zymberg S et al (2013) Safety and diagnostic accuracy of neuroendoscopic biopsies: an international multicenter study. J Neurosurg Pediatr 11:704–709. CrossRefGoogle Scholar
  34. 34.
    Chrastina J, Novak Z, Riha I et al (2014) Diagnostic value of brain tumor neuroendoscopic biopsy and correlation with open tumor resection. J Neurol Surg A 75:110–115. Google Scholar
  35. 35.
    Bander ED, Jones SH, Kovanlikaya I, Schwartz TH (2016) Utility of tubular retractors to minimize surgical brain injury in the removal of deep intraparenchymal lesions: a quantitative analysis of FLAIR hyperintensity and apparent diffusion coefficient maps. J Neurosurg 124:1053–1060. CrossRefGoogle Scholar
  36. 36.
    Day JD (2017) Transsulcal parafascicular surgery using brain path® for subcortical lesions. Neurosurgery 64:151–156. CrossRefGoogle Scholar
  37. 37.
    Moussazadeh N, Tsiouris AJ, Ramakrishna R (2016) Advanced imaging for biopsy guidance in primary brain tumors. Cureus. Google Scholar
  38. 38.
    Chiang GC, Kovanlikaya I, Choi C et al (2018) Magnetic resonance spectroscopy, positron emission tomography and radiogenomics—relevance to glioma. Front Neurol. Google Scholar
  39. 39.
    Salama GR, Heier LA, Patel P et al (2018) Diffusion weighted/tensor imaging, functional MRI and perfusion weighted imaging in glioblastoma—foundations and future. Front Neurol. Google Scholar
  40. 40.
    Sottoriva A, Spiteri I, Piccirillo SGM et al (2013) Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci 110:4009–4014. CrossRefGoogle Scholar
  41. 41.
    Patel AP, Tirosh I, Trombetta JJ et al (2014) Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344:1396–1401. CrossRefGoogle Scholar
  42. 42.
    Warnick RE, Longmore LM, Paul CA, Bode LA (2003) Postoperative management of patients after stereotactic biopsy: results of a survey of the AANS/CNS section on tumors and a single institution study. J Neurooncol 62:289–296CrossRefGoogle Scholar
  43. 43.
    Favre J, Taha JM, Burchiel KJ (2002) An analysis of the respective risks of hematoma formation in 361 consecutive morphological and functional stereotactic procedures. Neurosurgery 50:48–56 (discussion 56–57)Google Scholar
  44. 44.
    Tannock IF, Hickman JA (2016) Limits to personalized cancer medicine. N Engl J Med 375:1289–1294. CrossRefGoogle Scholar
  45. 45.
    Pisapia DJ, Magge R, Ramakrishna R (2017) Improved pathologic diagnosis—forecasting the future in glioblastoma. Front Neurol. Google Scholar
  46. 46.
    Tourneau CL, Delord J-P, Gonçalves A et al (2015) Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 16:1324–1334. CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Evan D. Bander
    • 1
  • Samuel H. Jones
    • 1
  • David Pisapia
    • 2
  • Rajiv Magge
    • 3
  • Howard Fine
    • 3
  • Theodore H. Schwartz
    • 1
    • 4
    • 5
  • Rohan Ramakrishna
    • 1
    Email author
  1. 1.Department of NeurosurgeryNewYork-Presbyterian/Weill Cornell MedicineNew YorkUSA
  2. 2.Department of PathologyNewYork-Presbyterian/Weill Cornell MedicineNew YorkUSA
  3. 3.Department of NeurologyNewYork-Presbyterian/Weill Cornell MedicineNew YorkUSA
  4. 4.Department of OtolaryngologyNewYork-Presbyterian/Weill Cornell MedicineNew YorkUSA
  5. 5.Department of NeuroscienceNewYork-Presbyterian/Weill Cornell MedicineNew YorkUSA

Personalised recommendations